Holen Sie sich die Stockscreener-App
43.92
1.70%
-0.76
Schlusskurs vom Vortag:
$44.68
Offen:
$44.68
24-Stunden-Volumen:
14.99M
Relative Volume:
0.73
Marktkapitalisierung:
$63.65B
Einnahmen:
$20.62B
Nettoeinkommen (Verlust:
$3.56B
KGV:
18.42
EPS:
2.3847
Netto-Cashflow:
$3.48B
1W Leistung:
+1.34%
1M Leistung:
-11.91%
6M Leistung:
-37.06%
1J Leistung:
-55.25%
1-Tages-Spanne:
$43.33
$44.84
1-Wochen-Bereich:
$42.72
$45.74
52-Wochen-Spanne:
$42.20
$105.65
Boston Scientific Corp Stock (BSX) Company Profile
Firmenname
Boston Scientific Corp
Sektor
Branche
Telefon
508-683-4000
Adresse
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, MDT, SYK, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
43.92 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
ABT
Abbott Laboratories
|
101.29 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
88.64 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
272.36 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
EW
Edwards Lifesciences Corp
|
86.29 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-30 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-10-03 | Herabstufung | Erste Group | Buy → Hold |
| 2025-09-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-16 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-16 | Hochstufung | Needham | Hold → Buy |
| 2025-01-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-10-18 | Herabstufung | Needham | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-02-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-06-30 | Eingeleitet | CL King | Buy |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-20 | Fortgesetzt | Citigroup | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-05-27 | Hochstufung | Needham | Hold → Buy |
| 2022-04-13 | Fortgesetzt | Truist | Buy |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-05-26 | Herabstufung | Needham | Buy → Hold |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-17 | Eingeleitet | Truist | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-04-22 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Buy |
| 2019-12-30 | Bestätigt | Cowen | Outperform |
| 2019-12-19 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-09-05 | Fortgesetzt | JP Morgan | Overweight |
| 2019-09-03 | Fortgesetzt | Barclays | Overweight |
| 2019-05-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-11-28 | Eingeleitet | UBS | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-10-02 | Bestätigt | Morgan Stanley | Overweight |
| 2018-09-07 | Bestätigt | Needham | Strong Buy |
| 2018-09-04 | Hochstufung | Jefferies | Hold → Buy |
| 2018-07-06 | Bestätigt | Needham | Strong Buy |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-04-26 | Bestätigt | Needham | Strong Buy |
Alle ansehen
Boston Scientific Corp Aktie (BSX) Neueste Nachrichten
Boston Scientific re-evaluates 2027 framework after cyberattack - scanx.trade
Boston Scientific Corp. stock underperforms Friday when compared to competitors - MarketWatch
Boston Scientific stock gains 2.06 percent ahead of the open - AD HOC NEWS
Boston Scientific stock faces a weaker 2026 growth outlook - AD HOC NEWS
Wells Fargo cuts Boston Scientific stock price target on cyberattack impact - Investing.com
Mexico Cardiac Rhythm Management Devices Market Outlook to 2036 Provides Revenue, Volume, Pricing and Competitive Insig - GlobeNewswire Inc.
Wells Fargo Adjusts Price Target on Boston Scientific to $48 From $50, Keeps Equalweight Rating - marketscreener.com
Boston Scientific stock slips before the bell after September 23 decline - AD HOC NEWS
Boston Scientific (BSX) Executive VP Arthur C. Butcher to Retire in January 2027 - GuruFocus
Boston Scientific (NYSE: BSX) Announces Arthur C. Butcher's Retirement with $780,000 Base Salary as Senior Advisor - Kalkine Media
Boston Scientific Corporation Announces Retirement of Arthur C. Butcher from Executive Vice President and Group President, Medsurg and Asia Pacific, Effective January 1, 2027 - marketscreener.com
Form 8K Boston Scientific Corp For: 23 September By Investing.com - Investing.com Nigeria
Boston Scientific announces retirement of executive vice president Arthur C. Butcher - Investing.com
Form 8K Boston Scientific Corp For: 23 September - Investing.com India
Arthur C. Butcher to Retire as Executive VP & Group President at Boston Scientific - TradingView
Boston Scientific stock advances 2.1 percent ahead of the open - AD HOC NEWS
Boston Scientific (BSX) Stock Moves 2.74%: What You Should Know - finance.yahoo.com
Boston Scientific Corp. stock outperforms competitors on strong trading day - MarketWatch
Boston Scientific stock holds near its yearly low after downgrade - ad-hoc-news.de
What Boston Scientific (BSX) Tells Us About the Healthcare Stocks Trade Right Now - Kalkine Media
Boston Scientific stock heads into the open after a 0.9% gain - ad-hoc-news.de
Boston Scientific stock holds steady as Oppenheimer cuts price target to USD 65 - ad-hoc-news.de
Oppenheimer Adjusts Price Target on Boston Scientific to $65 From $85, Maintains Outperform Rating - marketscreener.com
Boston Scientific stock holds steady as analysts weigh cyberattack impact - AD HOC NEWS
Citi downgrades Boston Scientific as cyberattack recovery compounds competitive pressure - MassDevice
Boston Scientific Shares Fall After Citigroup Downgrade - marketscreener.com
Boston Scientific (BSX) Stock Trades At A Discount On A 55% Slump - Yahoo Finance
Citi downgrades Boston Scientific on uncertain recovery path - Investing.com
Boston Scientific Can't Dislodge Rival's Heart Valve Patent - Law360
TD Cowen maintains Boston Scientific stock rating after cyberattack - Investing.com
Citigroup Downgrades Boston Scientific to Neutral From Buy, Adjusts PT to $50 From $57 - marketscreener.com
Boston Scientific Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Boston Scientific: A Great Company At A Deeply Discounted Price (Rating Upgrade) - Seeking Alpha
Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 15 Years - Benzinga
Boston Scientific Leans on Acquisitions to Drive Long-Term Growth - finance.yahoo.com
Boston Scientific Corp Share PriceBSX, RNS News, Articles, Quotes, & Charts (NYSE:BSX) - Proactive financial news
Boston Scientific (BSX) Didn’t Miss on Demand or Devices. A Cyberattack Just Broke Its Guidance. - Yahoo Finance
Why Did BSX Cut FY26 Guidance? CEO Details Three Unanticipated Factors At Bernstein Conference - Stocktwits
Boston Scientific stock falls as cyberattack clouds 2026 outlook - ad-hoc-news.de
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Boston Scientific fully restores operations after cyberattack - Yahoo Finance
What Is Moving the Story Around Boston Scientific (BSX)? - Kalkine Media
Why Boston Scientific (BSX) Dipped More Than Broader Market Today - Yahoo Finance
Boston Scientific Corp (BSX) Stock Down 4.1% -- Now Undervalued? GF Score: 77/100 - GuruFocus
Boston Scientific Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Alpha Buying: 4 Falling Knives Insiders Are Buying - Benzinga
Boston Scientific stock falls as cyberattack clouds 2026 guidance - ad-hoc-news.de
Boston Scientific at Wells Fargo conference: cyberattack clouds outlook By Investing.com - Investing.com India
Boston Scientific at Wells Fargo conference: cyberattack clouds outlook - Investing.com
Boston Scientific Corp at Wells Fargo Healthcare Conference Transcript - GuruFocus
Update on recent cybersecurity incident - Boston Scientific
Finanzdaten der Boston Scientific Corp-Aktie (BSX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
0.97%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):